A rare case of imatinib mesylate induced acute kidney injury

2016-07-27T05-12-55Z
Source: International Journal of Basic & Clinical Pharmacology
Ratna Agrawal, Kaustav Saha, Sabita Mohapatra.
Imatinib is a revolutionary targeted molecule strikingly successful in chronic phase of chronic myeloid leukemia and higher doses are beneficial in the accelerated phase of the disease. Its known adverse effects include abdominal pain, vomiting, fluid retention, periorbital edema, pleural effusion, myalgia, liver damage and congestive heart failure. Renal damage due to this drug has not been well reported. In this case, the patient developed acute kidney injury as evidenced by raised creatinine level after two months of administration of imatinib mesylate. At 4th visit, the levels of urea and creatinine were significantly above the upper normal limit. The patient was kept under supervision of his renal status and at the starting of 5th visit decision was made to change the drug from imatinib to nilotinib. Currently the patient is tolerating nilotinib well. Causality assessment using WHO scale revealed imatinib to have possibly caused this rare adverse reaction.


from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2ab7CyO
via IFTTT